- Home
- RDI vs LGVN Comparison
RDI vs LGVN Comparison
Compare RDI & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- LGVN
- Stock Information
- Founded
- RDI 1937
- LGVN 2014
- Country
- RDI United States
- LGVN United States
- Employees
- RDI N/A
- LGVN N/A
- Industry
- RDI Movies/Entertainment
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- RDI Consumer Discretionary
- LGVN Health Care
- Exchange
- RDI Nasdaq
- LGVN Nasdaq
- Market Cap
- RDI 30.1M
- LGVN 27.6M
- IPO Year
- RDI N/A
- LGVN 2021
- Fundamental
- Price
- RDI $1.25
- LGVN $1.46
- Analyst Decision
- RDI Hold
- LGVN Strong Buy
- Analyst Count
- RDI 1
- LGVN 3
- Target Price
- RDI $2.40
- LGVN $8.67
- AVG Volume (30 Days)
- RDI 42.0K
- LGVN 127.9K
- Earning Date
- RDI 05-14-2025
- LGVN 05-13-2025
- Dividend Yield
- RDI N/A
- LGVN N/A
- EPS Growth
- RDI N/A
- LGVN N/A
- EPS
- RDI N/A
- LGVN N/A
- Revenue
- RDI $210,527,000.00
- LGVN $2,392,000.00
- Revenue This Year
- RDI $11.97
- LGVN $1.30
- Revenue Next Year
- RDI $6.40
- LGVN $19.15
- P/E Ratio
- RDI N/A
- LGVN N/A
- Revenue Growth
- RDI N/A
- LGVN 237.38
- 52 Week Low
- RDI $1.17
- LGVN $0.77
- 52 Week High
- RDI $1.89
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- RDI 45.11
- LGVN 47.08
- Support Level
- RDI $1.18
- LGVN $1.20
- Resistance Level
- RDI $1.28
- LGVN $1.46
- Average True Range (ATR)
- RDI 0.08
- LGVN 0.15
- MACD
- RDI 0.00
- LGVN -0.00
- Stochastic Oscillator
- RDI 25.00
- LGVN 61.76
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.